- Research Tracker
- Supplement safety
- Vitamin C
What public sources say about the safety of vitamin C: FDA adverse-event reports, NIH guidance on interactions with medicines, and the registered trials that test it.
Interactions and safety, in NIH's words
Vitamin C supplements may interact with radiation therapy and medications, including chemotherapeutic agents and statins.
Vitamin C supplements have the potential to interact with several types of medications. A few examples are provided below. Individuals who are taking these medications on a regular basis should discuss their vitamin C intakes with their health care providers.
The safety and efficacy of using vitamin C and other antioxidants during cancer treatment is controversial [53,91,92]. Some data indicate that antioxidants might protect tumor cells from the action of radiation therapy and chemotherapeutic agents, such as cyclophosphamide, chlorambucil, carmustine, busulfan, thiotepa, and doxorubicin [54,91,93,94]. At least some of these data have been criticized because of poor study design [52]. Other data suggest that antioxidants might protect normal tissues from chemotherapy- and radiation-induced damage [91,93] and/or enhance the effectiveness of conventional cancer treatment [95]. However, due to the physiologically tight control of vitamin C, it is unclear whether oral vitamin C supplements could alter vitamin C concentrations enough to produce the suggested effects. Individuals who are undergoing chemotherapy or radiation should consult with their oncologist prior to taking vitamin C or other antioxidant supplements, especially in high doses [54].
Medicines covered in that section: Chemotherapy and radiation, 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins).
Quoted from the “Interactions with Medications” section: NIH Office of Dietary Supplements, health-professional fact sheet, retrieved 2026-11-16. Read the full page for the complete list and references.
FDA adverse-event reports (CAERS)
Matching rule: reports in the dietary-supplement category where a product marked "suspect" has a brand name containing “VITAMIN C”. Products that contain it without naming it are missed. Reports where it was only taken alongside the suspect product are not counted.
Combination products: 212 of the reports involve only products whose name lists another ingredient, such as calcium or a multivitamin. Their reactions may come from that other ingredient or from the tablet itself, so the reactions below count only the 209 reports where a product is named for vitamin C alone. This split is made from product names and can misfile some products. Most-reported products: Vitamin C (22); Naturemade Vitamin C (21); Naturemade Vitamin C 1000 Mg (15); Nature Made Super B-Complex With Vitamin C & Folic Acid (13); Nutrilite Vitamin C Extended Release (8); Nutrilite Vitamin C Plus Extended Release (7).
| Most reported reactions (single-ingredient products) | Reports |
|---|---|
| Dyspnoea | 37 |
| Choking | 33 |
| Foreign body | 19 |
| Nausea | 18 |
| Abdominal pain | 15 |
| Foreign body in throat | 13 |
| Diarrhoea | 13 |
| Dizziness | 13 |
| Oropharyngeal pain | 12 |
| Dysphagia | 12 |
| Pain | 12 |
| Pruritus | 12 |
Outcomes recorded in these reports (a report can have several): Other Serious or Important Medical Event (149), Visited a Health Care Provider (41), Visited Emergency Room (39), Hospitalization (35), Life Threatening (17), Other Outcome (15), Other Serious Outcome (10), Disability (10).
Source: openFDA food and supplement adverse events (CAERS), retrieved 2026-11-16.
Registered trials
42 trials in the non-drug evidence map test this class of supplement. Trials with posted results are listed first; each shows the condition it was registered for. A trial testing it in one condition says nothing about another.
- Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Completed Results posted
- Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer Completed Results posted
- Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria Completed Results posted
- Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes Completed Results posted
- Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer Terminated Results posted
- Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma Terminated Results posted
- Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease Terminated Results posted
- Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer Terminated Results posted
- High Dose Ascorbic Acid for Plasma Cell Disorders Completed
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients Completed
- Vitamin C Supplementation as a Preventive Treatment of Diabetic Peripheral Neuropathy Completed
- Evaluation of the Effect of Citicoline and Docosahexaenoic Acid (DHA) on the Visual Function of Patients With Glaucoma Completed
- Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C) Completed
- Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma Completed
- Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma Completed
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemi Completed
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder Completed
- Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study Completed
- Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women Completed
- Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants Completed